Table 3.
Test characteristics of cytology and HPV HC2 as secondary triage among VIA screen positive women with cut off of ≥CIN I and ≥CIN 2
| Test characteristics | Triage test | |||
|---|---|---|---|---|
| Cytology (≥ CIN I) | Cytology (≥ CIN 2) | HPV HC2 (≥ CIN I) | HPV HC2 (≥ CIN 2) | |
| Sensitivity (95% CI) | 22.2% (12-35.6%) | 66.7% (29.9-92.5%) | 18.5% (9.25-31.4%) | 77.8% (40.0-97.2%) |
| Specificity (95% CI) | 89.1% (83.6-93.3%) | 98.2% (95.5-99.5%) | 92.0% (86.9-95.6%) | 92.3% (87.9-95.4%) |
| Positive predictive value (95% CI) | 38.7% (21.8-57.8%) | 60% (26.2-87.8%) | 41.7% (22.1-63.4%) | 29.2% (12.6-51.1%) |
| Negative predictive value (95% CI) | 78.8% (72.4-84.3%) | 98.6% (96.0-99.7%) | 78.5% (72.3-84.0%) | 99% (96.5-99.9%) |
| False positive rates | 10.9% | 1.8% | 8.0% | 7.7% |
| False negative rates | 77.8% | 33.3% | 81.5% | 22.2% |
CIN=Cervical intraepithelial neoplasia; HPV HC2=Human papillomavirus hybrid capture 2 test